PLSE - NASDAQ

Pulse Biosciences, Inc.

PLSE·NASDAQ

$24.99

+1.3%

HealthcareMedical - Instruments & Supplies

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.73B

EPS-1.0800

P/E Ratio-23.14

Earnings Date08/11/2026

96.11M

Assets

-27%

3Y+23.0%

5Y+133.0%

10Y+265.0%

15.46M

Total Liabilities

-12%

3Y-81.0%

5Y-16.0%

10Y+1421.0%

80.66M

Total Equity

-30%

3Y-3688.0%

5Y+252.0%

10Y+219.0%

Pulse Biosciences, Inc. Funding & Solvency Profile

PLSE · NASDAQ

Current Assets

Cash & Cash Equivalents80.73M

Net Receivables274.00K

Inventory136.00K

Other Current Assets2.28M

Total Current Assets83 M

Non-Current Assets

Property, Plant & Equipment7.06M

Goodwill & Intangible Assets3.37M

Long-Term Investments0.00

Other Non-Current Assets691.00K

Total Non-Current Assets8 M

Total Assets

96.11M

Financial Health Analysis

Current Ratio

10.53x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.19x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

75 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

87% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Pulse Biosciences, Inc. Balance Sheet

PLSE • NASDAQ

Pulse Biosciences, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	80.7M	118M	44.4M	61.1M	28.6M	12.5M	6.9M	51.1M	3.4M	2.1M	3.6M	7M
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	8M	18.5M	8.5M	34.7M	14.3M	0.0	0.0
Cash & Short-Term Investments	80.7M	118M	44.4M	61.1M	28.6M	20.5M	25.4M	59.6M	38.1M	16.4M	3.6M	7M
Net Receivables	274K	0.0	0.0	0.0	61K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	274K	0.0	0.0	0.0	61K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	136K	0.0	0.0	0.0	5.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	2.1M	1.9M	1M	779K	412K	268K	44K	22.1K
Other Current Assets	2.3M	1.4M	963K	1M	0.0	0.0	0.0	0.0	0.0	0.0	347K	0.0
Total Current Assets	83.4M	119.4M	45.3M	62.1M	36.6M	22.3M	26.4M	60.4M	38.5M	16.7M	4M	7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	7.1M	8.3M	8.8M	10M	11.2M	11.9M	7.7M	2.2M	2.6M	317K	328.8K	190.4K
Goodwill	2.8M	2.8M	2.8M	2.8M	2.8M	2.8M	2.8M	2.8M	2.8M	2.8M	2.8M	2.8M
Intangible Assets	575K	1.2M	1.9M	2.6M	3.2M	3.9M	4.5M	5.2M	5.9M	6.5M	7.2M	7.9M
Goodwill & Intangible Assets	3.4M	4M	4.7M	5.3M	6M	6.7M	7.3M	8M	8.7M	9.3M	10M	10.7M
Long-Term Investments	0.0	0.0	1.9M	-2.7M	-3.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	1.6M	0.0	0.0	2.7M	3.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	691K	677K	-1.5M	365K	365K	365K	494K	101K	101K	0.0	0.0	9.8K
Total Non-Current Assets	12.7M	13M	13.8M	15.7M	17.6M	19M	15.5M	10.3M	11.3M	9.7M	10.3M	10.9M
Total Assets	96.1M	132.5M	59.2M	77.9M	54.2M	41.3M	41.9M	70.6M	49.8M	26.3M	14.3M	17.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2.8M	1.7M	1.8M	1.6M	2.9M	1.7M	2M	1.3M	782K	265K	262K	33.3K
Accounts Payable	2.8M	1.7M	1.8M	1.6M	2.9M	1.7M	2M	1.3M	782K	265K	262K	33.3K
Accrued Expenses	2M	5.8M	615K	2.5M	2.9M	2M	2.3M	1.4M	1M	751K	158K	92K
Short Term Debt	1.6M	0.0	0.0	917K	436K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	1.4M	1.1M	896K	774K	542K	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	16K	0.0	0.0	0.0	0.0	0.0	0.0	39.5K
Other Current Liabilities	1.6M	1.2M	3.2M	50K	1.5M	3.3M	234K	415K	397K	0.0	239.8K	39.5K
Total Current Liabilities	7.9M	10.1M	6.7M	6M	8.5M	7.6M	4.5M	3.1M	2.2M	1M	659.8K	164.8K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	65M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	1.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7M
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2M	1.6M	0.0	0.0	0.0
Total Non-Current Liabilities	7.5M	7.5M	8.1M	74.1M	10M	10.8M	6.7M	1.2M	1.6M	265K	262K	1.7M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-265K	-262K	0.0
Capital Lease Obligations	6M	8.9M	9.1M	10M	10.8M	11.4M	6.7M	0.0	0.0	0.0	0.0	0.0
Total Liabilities	15.5M	17.6M	14.8M	80.1M	18.6M	18.4M	11.2M	4.3M	3.8M	1M	659.8K	1.8M
SHAREHOLDERS' EQUITY
Common Stock	68K	66K	55K	37K	29K	25K	21K	142.1M	84.2M	13K	7.6K	7.6K
Additional Paid-In Capital	543.9M	505.3M	381.2M	292.4M	271.9M	195.4M	153.4M	142M	84.2M	37.9M	16.7M	16.3M
Retained Earnings	-463.3M	-390.5M	-336.9M	-294.7M	-236.2M	-172.5M	-122.7M	-75.7M	-38.2M	-12.6M	-3.1M	-276.6K
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	-1K	4K	-1K	-51K	-7K	0.0	0.0
Total Stockholders' Equity	80.7M	114.9M	44.4M	-2.2M	35.7M	22.9M	30.7M	66.3M	46M	25.3M	13.7M	16.1M
Total Equity	80.7M	114.9M	44.4M	-2.2M	35.7M	22.9M	30.7M	66.3M	46M	25.3M	13.7M	16.1M
SUMMARY
Total Liabilities & Equity	96.1M	132.5M	59.2M	77.9M	54.2M	41.3M	41.9M	70.6M	49.8M	26.3M	14.3M	17.9M
Total Investments	0.0	0.0	1.9M	-2.7M	-3.3M	8M	18.5M	8.5M	34.7M	14.3M	0.0	0.0
Total Debt	7.5M	8.9M	9.1M	76M	11.3M	11.4M	6.7M	0.0	0.0	0.0	0.0	0.0
Net Debt	-73.2M	-109.1M	-35.2M	14.8M	-17.4M	-1.1M	-180K	-51.1M	-3.4M	-2.1M	-3.6M	-7M
Shares Outstanding	67,767,572	67,767,572	67,767,572	67,767,572	67,767,572	67,767,572	67,767,572	67,767,572	67,767,572	67,767,572	67,767,572	67,767,572

SEC Filings

PLSE - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 14, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	May 11, 2026	June 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	April 30, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	April 27, 2026	April 25, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 16, 2026	April 16, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 09, 2026	April 08, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 07, 2026	April 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 27, 2026	March 23, 2026	2026	View Filing

Showing 1 to 10 of 247 filings

Related Guides

Blog Categories

Continue your PLSE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.